Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Ephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.69 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | RGS12 | O14924 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ephedrine SCHEMBL16196643 | 0.86 | ADRA1A (0.71) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Pseudoephedrine SCHEMBL16601218 | 0.86 | ADRA1A (0.71) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Racephedrine SCHEMBL28739755 | 0.83 | ADRA2C (0.92) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Ephedrine SCHEMBL4785 | 0.83 | CYP2D6 (1.00) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Racephedrine SCHEMBL12573578 | 0.83 | CYP2D6 (1.00) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Racephedrine SCHEMBL4786 | 0.83 | CYP2D6 (1.00) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Racephedrine SCHEMBL11906521 | 0.83 | CYP2D6 (1.00) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Ephedrine SCHEMBL4731265 | 0.83 | CYP2D6 (1.00) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Pseudoephedrine SCHEMBL4368 | 0.83 | CYP2D6 (1.00) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Racephedrine SCHEMBL4369 | 0.83 | CYP2D6 (1.00) | ADRA2CCHRM2ADRA1ARGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115272711-A | Device for detecting drugs by utilizing structural color of photonic crystal | 公安部物证鉴定中心 | 2022-11-01 | — | — | CN | disclosed |
| CN-115272710-A | Fast drug detection method, equipment and medium based on photonic crystal image | 公安部物证鉴定中心 | 2022-11-01 | — | — | CN | disclosed |
| EP-1817008-B1 | STABILIZED HME COMPOSITION WITH SMALL DRUG PARTICLES | UNIV TEXAS (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3368084-A1 | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL DELIVERY | Solubest Ltd (IL) | 2018-09-05 | — | — | EP | disclosed |
| US-9867786-B2 | Stabilized compositions containing alkaline labile drugs | AUXILIUM US HOLDINGS, LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9730894-B2 | Stabilized HME composition with small drug particles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170119660-A1 | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL DELIVERY | SOLUBEST LTD (IL) | 2017-05-04 | — | — | US | disclosed |
| WO-2017072774-A1 | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL DELIVERY | SOLUBEST LTD (IL) | 2017-05-04 | — | — | WO | disclosed |
| US-20170119669-A1 | STABILIZED HME COMPOSITION WITH SMALL DRUG PARTICLES | UNIV TEXAS (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2010366-B1 | PROCESS FOR THE PREPARATION OF A HOT-MELT EXTRUDED LAMINATE | AUXILIUM INT HOLDINGS INC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-1248598-A4 | OSMOTIC DEVICE HAVING A PREFORMED PASSAGEWAY THAT INCREASES IN SIZE | OSMOTICA CORP (VG) | 2004-01-21 | — | — | EP | disclosed |
| EP-0914098-B1 | MULTI-LAYERED OSMOTIC DEVICE | OSMOTICA CORP (VG) | 2003-10-01 | — | — | EP | disclosed |
| US-6599284-B2 | Osmotic device having a preformed passageway that increases in size | OSMOTICA CORP. (VG) | 2003-07-29 | — | — | US | disclosed |
| EP-1248598-A1 | OSMOTIC DEVICE HAVING A PREFORMED PASSAGEWAY THAT INCREASES IN SIZE | Osmotica Corp. (VG) | 2002-10-16 | — | — | EP | disclosed |
| US-20020099361-A1 | Osmotic device having a preformed passageway that increases in size | CIBC BANK USA, AS ADMINISTRATIVE AGENT | 2002-07-25 | — | — | US | disclosed |
| EP-0914098-A4 | MULTI-LAYERED OSMOTIC DEVICE | PHOENIX U S A INC LAB (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001052819-A1 | OSMOTIC DEVICE HAVING A PREFORMED PASSAGEWAY THAT INCREASES IN SIZE | OSMOTICA CORP. (VG) | 2001-07-26 | — | — | WO | disclosed |
| US-6004582-A | FOR IMMEDIATE DELIVERY OF A FIRST ACTIVE AGENT FOLLOWED BY A MONITORED, CONTINUOUS, CONTROLLED AND/OR RETARDED DELIVERY OF A SECOND ACTIVE AGENT WHICH IS THE SAME OR DIFFERENT AS THE FIRST ACTIVE AGENT; TIME-RELEASE AGENTS | LABORATORIOS PHOENIX U.S.A, INC. (AR) | 1999-12-21 | — | — | US | disclosed |
| EP-0914098-A1 | MULTI-LAYERED OSMOTIC DEVICE | Laboratorios Phoenix U.S.A., Inc. (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998053802-A1 | MULTI-LAYERED OSMOTIC DEVICE | LABORATORIOS PHOENIX U.S.A., INC. (US) | 1998-12-03 | — | — | WO | disclosed |